1 / 2

Japanese Society of Hematology ＣＯ Ｉ disclosure presenter ：　○○　○○

[Sample of a slide for oral presentations] If you have no relevant financial relationship to disclose. Japanese Society of Hematology ＣＯ Ｉ disclosure presenter ：　○○　○○. I have no relevant financial relationship to disclose. [Sample of a slide for oral presentations]

lakia
Download Presentation

Japanese Society of Hematology ＣＯ Ｉ disclosure presenter ：　○○　○○

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. [Sample of a slide for oral presentations] If you have no relevant financial relationship to disclose Japanese Society of Hematology ＣＯ Ｉ disclosurepresenter：　○○　○○ I have no relevant financial relationship to disclose.

  2. [Sample of a slide for oral presentations] If you have any relevant financial relationships to disclose: Japanese Society of Hematology ＣＯ Ｉ disclosurepresenter：　○○　○○ I have the following relationships to disclose. (1) Employment/Leadership position/Advisory role: No (2) Stock ownership or options: No (3) Patent royalties/licensing fees: No (4) Honoraria: No (5) Manuscript fees: No (6) Research funding: Yes, ABC Pharmaceuticals (7) Subsidies or Donations: No (8) Endowed departments by commercial entities: Yes, XYZ Corporation (9) Travel fees, gifts, and others: No (10) Supplied with reagents, drugs, etc: eg, Drug A is kindly provided by XYZ Pharmaceuticals. (11) Off-label use: eg, This study includes off-label use of drug B in the treatment of disease C. IRB has approved this protocol.

More Related